Whitehawk Therapeutics, Inc.

As of June 30, 2026, Whitehawk Therapeutics, Inc. carries a market capitalization of 230.32M, placing it among publicly traded companies globally. Its enterprise value stands at 64.03M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Whitehawk Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Whitehawk Therapeutics, Inc. has 57.01M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Whitehawk Therapeutics, Inc. maintains a current ratio of 17.38, meaning it holds 17.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Whitehawk Therapeutics, Inc. posted a negative return on equity (ROE) of -44.98, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -42.60, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 27.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Whitehawk Therapeutics, Inc.'s stock has gained approximately 43.14% over the past 52 weeks. The 50-day moving average sits at 3.52, while the 200-day moving average is 3.33.

Over the twelve months ended June 30, 2026, Whitehawk Therapeutics, Inc. generated - - in revenue and converted that into -69.88M in net income, yielding earnings per share of -0.96. EBITDA reached -75.32M, while operating income came in at -75.33M.

These figures are as of June 30, 2026. Total book value stands at 160.11M, with working capital of 158.73M providing operational flexibility.

Whitehawk Therapeutics, Inc. produced -60.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -60.70M - equivalent to -0.84 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -20.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -31.11, meaning Whitehawk Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Whitehawk Therapeutics, Inc.'s most recent stock split took place on August 27, 2021 with a 15:1 split ratio.

As of June 30, 2026, Whitehawk Therapeutics, Inc. has an Altman Z-Score of 11.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.